Cellectar Biosciences (CLRB) stock

Worth $11.5MShares as of Aug 11

$1.22

-4.69%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score CLRB. It is too small and too thinly traded for a fair Quality Score.

Healthcare · Biotech

NextQ1 2027“first patients in the confirmatory Phase 3 trial of iopofosine I 131 in first quarter 2027…”Trial start · SEC filing · Nov 10

Follow CLRB's trial news. Pro members can get an alert when Cellectar Biosciences files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CLRB files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

What's next for CLRB, and how long its cash lasts

Next step the company has named

Q1 2027“first patients in the confirmatory Phase 3 trial of iopofosine I 131 in first quarter 2027 and to file for accelerated approval with”Trial start · SEC filing · Nov 10

What it means: when a trial begins, or reaches the stage the company named.

Lead program: iopofosine I 131
Another trial: Evaluation of Iopofosine I 131 vs. R-CD in WM PatientsPhase 3 · Not yet recruiting · 219 people · main data estimated Jan 2032 · NCT07766421

4 more trials, 2 more milestones and 40 filings, for Pro members.

Cash runway

The company says its cash lasts into the second quarter of 2027 (8-K, Aug 13).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed May 24, 2024)
At-the-market share sales program (S-3, filed May 24, 2024)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Chief Operating Officer Jarrod Longcor bought 8,680 shares on May 7. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

Get an alert when James V buys or sells

For Pro members: every trade, and James V’s 4 filings and quotes.

Get an alert when CLRB files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

CLRB's latest filings

Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates8-K, filed Nov 10
Quarterly report10-Q, filed Nov 10
9 insider filingsForm 4, filed Jul 8

18 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why CLRB isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. CLRB is worth about $11.5M and trades about 175,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.